Updated level IVa contouring reduced predicted hypothyroidism risk in nasopharyngeal cancer
Updated level IVa delineation reduced predicted hypothyroidism from 43.9% to 34.9% without compromising target coverage.
Updated level IVa delineation reduced predicted hypothyroidism from 43.9% to 34.9% without compromising target coverage.
Five-year vaginal recurrence was 3.6% without verification imaging, versus 1.6% reported in the separate PORTEC-4a brachytherapy cohort.
Across 53 countries, workforce retention was shaped by culture, leadership, career development, resource strain, recognition and burnout.
Across 27 years of COG trials, IMRT/VMAT replaced 3D photons while proton use expanded to nearly 40% of radiotherapy patients.
Unopposed progesterone use was associated with eightfold higher odds of tumor-related visual deficit among women referred for meningioma radiotherapy.
At ten years after prostate LDR brachytherapy, 85% of respondents remained satisfied, while bowel quality of life remained independently associated with satisfaction.
Tumor volume and OAR proximity drove brain metastasis fractionation, while preoperative SRS showed a substantial preference-to-practice gap.
Patients with clinician-documented fatigue had 39% lower odds of completing electronic fatigue assessments, exposing an important limitation of PRO-only monitoring.
Irradiating more than half of the axillary-lateral thoracic junction to 35 Gy was independently associated with a threefold higher lymphedema risk.
Modeling relationships between CT radiomic features improved distant-metastasis prediction over conventional radiomics across independent head and neck cancer cohorts.
Each 1-Gy increase in estimated immune-cell dose was associated with 66% higher breast cancer mortality after multivariable adjustment.
Administrative burden and staffing concerns were widespread, while reimbursement dominated private-practice concerns and unstable research funding dominated physician-scientist concerns.
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
In 201 recurrent glioblastomas, 80% required no more than 10.4 mm expansion to encompass 80% of recurrence volume.
Substantial physician-dependent dose variation meant treatment-group assignment did not consistently reflect the dose actually delivered to regional nodes.